MEDP vs. TAK: Medpace vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Medpace (MEDP) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while TAK is classified in Pharmaceuticals.

Medpace (MEDP) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Medpace (MEDP) has a non-negative beta of 1.10.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Medpace (MEDP) at 117.88% clears its industry range for ROE, a sharper capital-efficiency signal than Takeda Pharmaceutical (TAK) at 0.56%, which is closer to a typical peer reading.

Medpace (MEDP) at 18.24% converts revenue to bottom-line profit above its industry’s benchmark range, while Takeda Pharmaceutical (TAK) at 0.87% keeps roughly the typical share for its industry.

Both Medpace (MEDP) at 23.12% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Medpace (MEDP) at 19.97% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Medpace (MEDP) at 20.98% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Both Medpace (MEDP) at 0.83 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Medpace (MEDP) at 0.29 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Medpace (MEDP) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Medpace (MEDP) at 36.26 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Medpace (MEDP) at 6.44 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile relative to book while Medpace (MEDP) at 31.23 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics